JP2007532548A - バゼドキシフェンアセテートの結晶質多形体 - Google Patents

バゼドキシフェンアセテートの結晶質多形体 Download PDF

Info

Publication number
JP2007532548A
JP2007532548A JP2007507417A JP2007507417A JP2007532548A JP 2007532548 A JP2007532548 A JP 2007532548A JP 2007507417 A JP2007507417 A JP 2007507417A JP 2007507417 A JP2007507417 A JP 2007507417A JP 2007532548 A JP2007532548 A JP 2007532548A
Authority
JP
Japan
Prior art keywords
composition
polymorph
bazedoxifene acetate
mixture
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007507417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532548A5 (cg-RX-API-DMAC7.html
Inventor
アリ,カデュム,エー.
アレグリニ,ピエトロ
ベリ,アルド
ブレシェロ,ロベルト
カナタ,ヴィンセンゾ
チブウィー,マラマ,ケー.
コタルカ,リヴィウス
ガンゴリ,シュリドハー,ジー.
ロングフェロウ,カール,イー.
ソリアト,ジョージオ
ヴァージニ,マシモ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007532548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2007532548A publication Critical patent/JP2007532548A/ja
Publication of JP2007532548A5 publication Critical patent/JP2007532548A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007507417A 2004-04-07 2005-04-06 バゼドキシフェンアセテートの結晶質多形体 Abandoned JP2007532548A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56058404P 2004-04-07 2004-04-07
PCT/US2005/011423 WO2005100314A1 (en) 2004-04-07 2005-04-06 Crystalline polymorph of bazedoxifene acetate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008171116A Division JP2009007361A (ja) 2004-04-07 2008-06-30 バゼドキシフェンアセテートの結晶質多形体

Publications (2)

Publication Number Publication Date
JP2007532548A true JP2007532548A (ja) 2007-11-15
JP2007532548A5 JP2007532548A5 (cg-RX-API-DMAC7.html) 2008-08-14

Family

ID=34965585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007507417A Abandoned JP2007532548A (ja) 2004-04-07 2005-04-06 バゼドキシフェンアセテートの結晶質多形体
JP2008171116A Withdrawn JP2009007361A (ja) 2004-04-07 2008-06-30 バゼドキシフェンアセテートの結晶質多形体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008171116A Withdrawn JP2009007361A (ja) 2004-04-07 2008-06-30 バゼドキシフェンアセテートの結晶質多形体

Country Status (20)

Country Link
US (1) US7683052B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732889A1 (cg-RX-API-DMAC7.html)
JP (2) JP2007532548A (cg-RX-API-DMAC7.html)
KR (1) KR20070004815A (cg-RX-API-DMAC7.html)
CN (1) CN1938271A (cg-RX-API-DMAC7.html)
AR (1) AR048683A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005233114A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509257A (cg-RX-API-DMAC7.html)
CA (1) CA2561296A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066910A (cg-RX-API-DMAC7.html)
GT (1) GT200500080A (cg-RX-API-DMAC7.html)
IL (1) IL178101A0 (cg-RX-API-DMAC7.html)
NO (1) NO20065046L (cg-RX-API-DMAC7.html)
PA (1) PA8629201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060173A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006132352A (cg-RX-API-DMAC7.html)
TW (1) TW200536845A (cg-RX-API-DMAC7.html)
UA (1) UA86055C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005100314A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200608361B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011037832A (ja) * 2009-06-23 2011-02-24 Wyeth Llc 酢酸バゼドキシフェンの多形フォームd及びその製造方法
JP2011511843A (ja) * 2008-02-11 2011-04-14 ワイス・エルエルシー バゼドキシフェン酢酸塩の多形体aの調製方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003623A1 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
CN101304731B (zh) * 2005-08-24 2012-06-20 惠氏公司 醋酸苯卓昔芬制剂及其生产方法
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
US20100016290A1 (en) * 2008-02-11 2010-01-21 Livius Cotarca Amorphous polymorph of bazedoxifene acetate
EP2493477B1 (en) 2009-10-27 2013-10-16 Wyeth LLC Bazedoxifene formulations with antioxidants
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
US9212172B2 (en) 2010-09-14 2015-12-15 Dr. Reddy's Laboratories Limited Preparation of crystalline bazedoxifene and its salts
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
CN103864664A (zh) * 2012-12-18 2014-06-18 江苏柯菲平医药有限公司 巴多昔芬乙酸盐新晶型及其制备方法
WO2014186325A1 (en) 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
CN103864665B (zh) * 2014-03-04 2016-03-02 苏州特瑞药业有限公司 醋酸巴多昔芬的制备方法
CN104030963A (zh) * 2014-06-30 2014-09-10 四川大学 一种巴多昔芬醋酸盐晶型a的制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
SK281737B6 (sk) 1996-04-19 2001-07-10 American Home Products Corporation 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
PT1025077E (pt) 1997-10-15 2007-05-31 Wyeth Corp Novas ariloxi-alquil-dialquilaminas
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
JP2005535623A (ja) 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療における、チオ−オキシインドール誘導体の使用
RU2006132180A (ru) 2004-04-07 2008-05-20 Вайет (Us) Кристаллический полиморф базедоксифен ацетата

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511843A (ja) * 2008-02-11 2011-04-14 ワイス・エルエルシー バゼドキシフェン酢酸塩の多形体aの調製方法
JP2011037832A (ja) * 2009-06-23 2011-02-24 Wyeth Llc 酢酸バゼドキシフェンの多形フォームd及びその製造方法
JP2016033165A (ja) * 2009-06-23 2016-03-10 ワイス・エルエルシー 酢酸バゼドキシフェンの多形フォームd及びその製造方法
JP2017137360A (ja) * 2009-06-23 2017-08-10 ワイス・エルエルシー 酢酸バゼドキシフェンの多形フォームd及びその製造方法
JP2018162327A (ja) * 2009-06-23 2018-10-18 ワイス・エルエルシー 酢酸バゼドキシフェンの多形フォームd及びその製造方法

Also Published As

Publication number Publication date
RU2006132352A (ru) 2008-05-20
TW200536845A (en) 2005-11-16
ECSP066910A (es) 2006-12-20
CN1938271A (zh) 2007-03-28
EP1732889A1 (en) 2006-12-20
PE20060173A1 (es) 2006-04-12
PA8629201A1 (es) 2005-11-25
BRPI0509257A (pt) 2007-09-11
GT200500080A (es) 2005-10-31
AU2005233114A1 (en) 2005-10-27
IL178101A0 (en) 2006-12-31
UA86055C2 (ru) 2009-03-25
ZA200608361B (en) 2010-03-31
NO20065046L (no) 2006-11-06
KR20070004815A (ko) 2007-01-09
WO2005100314A1 (en) 2005-10-27
CA2561296A1 (en) 2005-10-27
US20050250762A1 (en) 2005-11-10
AR048683A1 (es) 2006-05-17
US7683052B2 (en) 2010-03-23
JP2009007361A (ja) 2009-01-15

Similar Documents

Publication Publication Date Title
JP2009007361A (ja) バゼドキシフェンアセテートの結晶質多形体
JP2009035535A (ja) バゼドキシフェンアセテートの結晶多形
JPH09512283A (ja) 抗片頭痛インドール誘導体塩類
US20090137559A1 (en) Bazedoxifene ascorbate
JP2002505254A (ja) パロキセチン塩
EP1880992A1 (en) Stable modifications of tegaserod hydrogen maleate
CN1938272A (zh) 巴泽多昔芬醋酸盐的结晶多晶型物
MX2007001510A (es) Polimorfo cristalino de clorhidrato de pipindoxifeno monohidratado.
MXPA06011717A (en) Crystalline polymorph of bazedoxifene acetate
MXPA06011716A (en) Crystalline polymorph of a bazedoxifene acetate
MX2007001506A (es) Polimorfo cristalino del clorhidrato de pipindoxifeno monohidratado.
HK1099651A (en) Crystalline polymorph of a bazedoxifene acetate
US4593047A (en) Process for the preparation of 3-trifluoromethyl-and 2,5-dimethyl-4'-hdyroxy-α-ethyl-benzhydrol, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080630

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080630

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20080724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20090403

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20090728